The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 22, 2022

Filed:

Feb. 28, 2019
Applicant:

Yuhan Corporation, Seoul, KR;

Inventors:

Kwang-Hoon Lee, Gyeonggi-do, KR;

June Hyung Lee, Seoul, KR;

Na Rae Lee, Seoul, KR;

Eunjeong Jeong, Gyeonggi-do, KR;

Young Bong Park, Gyeonggi-do, KR;

Nakho Chang, Chungcheongbuk-do, KR;

Eun-Jung Lee, Gyeonggi-do, KR;

Ki Hong Kim, Gyeonggi-do, KR;

Sunghyun Choi, Gyeonggi-do, KR;

Byung Hyun Choi, Gyeonggi-do, KR;

Ju Young Park, Seoul, KR;

Moo Young Song, Gyeonggi-do, KR;

Jong-Seo Lee, Gyeonggi-do, KR;

Kyu-Tae Kim, Gyeonggi-do, KR;

Bong-Kook Ko, Seoul, KR;

Assignee:

YUHAN CORPORATION, Seoul, KR;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/00 (2006.01); C07K 16/46 (2006.01); C07H 21/04 (2006.01); C12N 5/02 (2006.01); C12N 5/20 (2006.01); C12N 15/00 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); A61K 2039/505 (2013.01); C07K 2317/33 (2013.01); C07K 2317/52 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01);
Abstract

Disclosed are a novel antibody specifically binding to the tumor-immunosuppressant, TIGIT (T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif [ITIM] domain) or an antigen-binding fragment thereof, a nucleic acid encoding the antibody or the antigen-binding fragment thereof, a vector and a host cell including the nucleic acid, a method for producing the antibody or the antigen-binding fragment thereof, a pharmaceutical composition containing the antibody or the antigen-binding fragment thereof as an active ingredient, and uses of the pharmaceutical composition. The antibody specifically binding to TIGIT or the antigen-binding fragment thereof and the pharmaceutical composition containing the same as an active ingredient are preferably used for the treatment of cancer or tumors.


Find Patent Forward Citations

Loading…